Literatur
- 1
Werbeanzeige der Firma Bayer AG für Acarbose.
Der Internist.
2003;
44
713
- 2 The STOP-NIDDM trial. Powerpoint-Folienvortrag. http://www.stop-niddm.com/study/slides.htm.
Zugriff: 1. August 2003; teilweise jetzt verfügbar unter http://www.di-em.de
- 3
Chiasson J L. et al .
Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular
disease in subjects with impaired glucose tolerance: Facts and interpretations
concerning the critical analysis of The STOP-NIDDM Trial data.
Diabetologia.
2004;
47
(im Druck)
- 4
Hanefeld M. et al .
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:
meta-analysis of seven long-term studies.
Eur Heart J.
2004;
25
10-16
- 5
Kaiser T, Sawicki P T.
Acarbose for prevention of diabetes, hypertension and cardiovascular events?
A critical analysis of the STOP-NIDDM data.
Diabetologia.
2004;
47
575-580
Thomas Kaiser
DIeM - Institut für evidenzbasierte Medizin
Venloer Straße 301-303
50823 Köln
Phone: 0221/86967313
Fax: 0221/86967319
Email: t.kaiser@di-em.de
URL: http://www.di-em.de
